Last edition
News about "investigational oral therapy "
MerryLife Biomedical Reports Positive Phase I Data for Oral Alzheimer's Therapy TML-6
MerryLife Biomedical’s investigational oral therapy TML-6 demonstrated favourable safety and tolerability in Phase I, paving the way for a 210-patient global Phase II trial in early Alzheimer’s disease.
Investigational Oral Therapy | 10/02/2026 | By News Bureau | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members